TY  - CHAP
M1  - Book, Section
TI  - Chapter 323. Antiparasitic Therapy
A1  - Held, Melissa
A1  - Cappello, Michael
A2  - Rudolph, Colin D.
A2  - Rudolph, Abraham M.
A2  - Lister, George E.
A2  - First, Lewis R.
A2  - Gershon, Anne A.
Y1  - 2011
N1  - 
T2  - Rudolph's Pediatrics, 22e
AB  - Parasitic  diseases  afflict  more  than  2  billion  people  worldwide  and  are  among  the  leading  causes  of  death  and  chronic  morbidity  in  resource-limited  countries.  Because  parasites  collectively  represent  a  wide  array  of  species,  effective  therapy  of  infections  caused  by  these  evolutionarily  distinct  eukaryotes  requires  an  equally  diverse  armamentarium  of  pharmacologic  agents.  The  past  decade  has  seen  a  renewed  commitment  to  antiparasitic  drug  development,  spearheaded  by  novel  public-private  partnerships  and  supported  by  international  philanthropic  organizations,  a  commitment  that  may  ultimately  yield  new  agents  for  these  globally  important  diseases.1-3  Equally  encouraging  is  the  recent  recognition  that  integrated  control  of  multiple  tropical  diseases  can  be  achieved  through  periodic  administration  of  inexpensive,  orally  available  medicines  to  at-risk  individuals  living  in  endemic  communities.4,5  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspediatrics.mhmedical.com/content.aspx?aid=7030800
ER  -